Pfizer wants Talzenna for first-line castration-resistant prostate cancer unrestricted by biomarkers, but the FDA questioned the study design behind the application ahead of an advisory committee review. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
